Flash FinanceUS
Market closed S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · MoonLake Immunotherapeutics (MLTX)

MoonLake submits BLA for sonelokimab in hidradenitis suppurativa to FDA

Neutral Impact 3 of 5 legal/regulatory Written later

MoonLake Immunotherapeutics said it submitted a Biologics License Application to the U.S. Food and Drug Administration on September 30, 2026, seeking approval of its tri-specific nanobody sonelokimab for moderate-to-severe hidradenitis suppurativa in adults and patients 12 years and older. The filing marks a regulatory step toward a possible approval, but the FDA has not yet decided whether to accept the application for review.

Key points

  • BLA submitted to the FDA on September 30, 2026 for sonelokimab in moderate-to-severe hidradenitis suppurativa
  • FDA acceptance decision expected within approximately 60 days of submission
  • Planned review timeline expected from the FDA within approximately 74 days of submission

The filing

CompanyMoonLake Immunotherapeutics (MLTX)
Form8-K, current report
Filed with the SECSep 30, 2026, 4:15 PM ET
Accession number0001213900-26-105240

Items reported: 8.01 Other Events

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 11:43 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on September 30, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.